27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Of 5687 unique abstracts, 255 were selected for full-text review, and 57 studies, representing 20 892 patients, met all inclusion criteria. 5 key findings →
Participants: 892 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The association between BMI and dementia is likely to be attributable to two different processes: a harmful effect of higher BMI, which is observable in long follow-up, and a reverse-causation effect that makes a higher BMI to appear protective when the follow-up is short. 1 key finding →
Design: cohort study Participants: 6,894 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study found no evidence of a neuroprotective effect of physical activity. 4 key findings →
Design: cohort study Participants: 329 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities are frequent on neuroimaging of older people and are a key feature of cerebral small vessel disease. 1 key finding →
Design: meta-analysis Participants: 4,006 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Compared with the reference standard for diagnosing delirium, 2 study nurses using the CAM-ICU had sensitivities of 100% and 93%, specificities of 98% and 100%, and high interrater reliability (kappa = 0.96; 95% confidence interval, 0.92-0.99). 3 key findings →
Design: cohort study Participants: 111 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As with incidences, HRs were higher in patients who had more severe COVID-19 (eg, those admitted to ITU compared with those who were not: 1·58, 1·50-1·67, for any diagnosis; 2·87, 2·45-3·35, for any first diagnosis). 3 key findings →
Design: cohort study Participants: 379 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although preliminary, our findings have implications for clinical services, and prospective cohort studies are warranted. 3 key findings →
Design: cohort study Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Reductions in cerebral glucose metabolic rate (CMRglu) as measured by fludeoxyglucose F 18-positron emission tomography (FDG-PET) in parietotemporal, frontal, and cingulate cortices are associated with increased AD risk and can be observed years before dementia onset. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642-0.813; Pdiff ≤ 0.029). 5 key findings →
Participants: 135 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A mean value of 85.7% was achieved for overall diagnostic accuracy, 82.4% for positive predictive value, and 87.5% for negative predictive value. 2 key findings →
Participants: 94 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Incidence rates for AD in the BLSA are consistent with published rates in other studies. 2 key findings →
Design: longitudinal study Participants: 1,236 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. 3 key findings →
Participants: 725 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). 4 key findings →
Design: longitudinal study Participants: 146 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The mean (SD) age of the study population sample (N = 3496) was 76.4 (7.6) years, and 2095 participants (60%) were female. 5 key findings →
Design: cross-sectional Participants: 3,496 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared with respective matched nonusers, individuals receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%-6.6%; P Conclusions and relevance The absolute effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported and increases with dose. 5 key findings →
Design: case-control study Participants: 90,786 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In secondary analyses, the area under the curve (AUC) of [18F]flortaucipir SUVR was compared with 3 established magnetic resonance imaging measures (hippocampal volumes and AD signature and whole-brain cortical thickness), and sensitivity and specificity of [18F]flortaucipir in MCI due to AD vs non-AD neurodegenerative disorders were determined. 3 key findings →
Design: cross-sectional Participants: 719 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four hundred ninety-four individuals eventually developed dementia and 427 (86%) of these persons were admitted at least once; 2525 remained free of dementia and 1478 (59%) of those were admitted at least once. 4 key findings →
Design: cohort study Participants: 3,019 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. 4 key findings →
Design: cohort study Participants: 2,929 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found a significant association between GBA1 mutation carrier status and DLB, with an odds ratio of 8.28 (95% CI, 4.78-14.88). 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Delirium can accelerate the trajectory of cognitive decline in patients with Alzheimer disease (AD). 2 key findings →
Design: prospective cohort Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. 3 key findings →
Design: case-control study Participants: 770 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population. 3 key findings →
Design: open-label trial Participants: 176 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared with the usual care clinics (12-month incidence, 213 of 1724 [12.4%]), the odds of an incident ADRD diagnosis were higher in the clinics randomized to QDRS plus PDM (12-month incidence, 355 of 2301 [15.4%]; adjusted odds ratio [AOR], 1.31; 95% CI, 1.05-1.64) but not the clinics randomized to PDM only (12-month incidence, 134 of 1300 [10.3%]; AOR, 0.84; 95% CI, 0.63-1.11]). 3 key findings →
Design: RCT Participants: 5,325 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. 5 key findings →
Design: systematic-review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →